research Diffuse plate-like sheets of desquamation
The rash resolved after stopping ponatinib.
Search
for
Sort by
Research
330-360 / 1000+ resultsresearch Multimodal therapeutic approach for a severe case of kaposiform lymphangiomatosis from procedural interventions to targeted therapies
Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.
research Intralesional methotrexate in patchy alopecia areata: trichoscopic evaluation and effect on lesional tumour necrosis factor alpha
Intralesional methotrexate effectively treats patchy alopecia areata by reducing inflammation.
research An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report
Mogamulizumab treatment in Sézary syndrome may cause skin issues and hair loss but can lead to a complete response.
research Efficacy of luliconazole combination shampoo in patients with seborrheic dermatitis
The luliconazole shampoo effectively reduces symptoms of seborrheic dermatitis and is well-tolerated.
research Systemic tofacitinib in paediatric alopecia areata
research Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO ‐LT phase 3, open‐label study
Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
research Immune-Mediated Skin Reactions Induced by Recombinant Antibodies and Other TNF-Alpha Inhibitors
TNF-alpha inhibitors can cause various immune-related skin issues.
research Cytotoxicity of bendamustine, alone and in combination with novel agents, toward adult T-cell leukemia cells
Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.
research Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-centre Real-world Retrospective Study
Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.
research 128 Bimekizumab led to rapid & deep normalisation of molecular signatures associated with PASI sub-components, preceding clinical skin clearance
The study investigated the effects of bimekizumab (BKZ) on psoriatic skin, focusing on the Psoriasis Area and Severity Index (PASI) sub-components: erythema, thickness, and scaling. In the BE RADIANT trial, patients receiving BKZ showed significant reductions in these sub-scores by Week 8, with ≥95% improvement by Week 12, maintained through Week 48. Molecular analysis revealed complete normalization of gene signatures associated with these sub-components by Week 8. The study found a correlation between changes in interleukin (IL)17A/IL17F expression and gene expression changes, highlighting BKZ's impact on keratinocytes. The results demonstrate that molecular resolution precedes clinical skin clearance, with all sub-components being reliable indicators of BKZ response.
research Upadacitinib Efficacy for the Treatment of Concomitant Psoriasis and Alopecia Areata
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
research Adalimumab‐induced scalp psoriasis with severe alopecia
Stopping adalimumab and starting methotrexate with topical treatments improved the woman's scalp psoriasis and hair regrew.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research ‘Ritlecitinib: unveiling hair regrowth for alopecia areata’
Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
research Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis
Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
research Eyelash trichomegaly complicating pembrolizumab for colorectal cancer
Pembrolizumab can cause unusual eyelash growth, but it may still be worth continuing if cancer treatment is effective.
research Characteristics and Outcomes of Patients on Tofacitinib for Alopecia Areata or Rheumatoid Arthritis: A Retrospective Cohort Study
Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research An In Situ Chemotherapy Drug Combined with Immune Checkpoint Inhibitor for Chemoimmunotherapy
Combining specific nanoparticles with immune therapy significantly improves cancer treatment.
research Alopecia areata mit gutem Ansprechen auf Tofacitinib
Tofacitinib helped regrow hair in a woman with alopecia areata.
research JAK inhibitors in dermatology: The promise of a new drug class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus
Thalidomide improved lupus symptoms but caused nerve damage in some patients.
research Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.
research Biologics in the management of childhood atopic dermatitis
Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
research Successful management of Netherton syndrome using IVIG and dupilumab: A case report
A young boy with Netherton syndrome improved significantly using IVIG, dupilumab, and dietary changes.
research IMAGING INSIGHTS INTO JC VIRUS-ASSOCIATED PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN NEUROPSYCHIATRIC LUPUS: A CASE REPORT
Careful monitoring is crucial to prevent JC virus reactivation in lupus patients treated with rituximab.
research Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Alopecia secondary to anti-tumor necrosis factor-alpha therapy
Anti-TNF therapy can cause hair loss and skin issues.
research Cost‐Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan
Ritlecitinib is cost-effective for severe alopecia areata in Japan.